{"organizations": [], "uuid": "9e6aea82f9f6fb42786a1957c5b7180a910659a3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-g1-therapeutics-announces-initiati/brief-g1-therapeutics-announces-initiation-of-phase-1b-2-clinical-trial-of-g1t38-in-combination-with-tagrisso-idUSASC09VVP", "country": "US", "domain_rank": 408, "title": "BRIEF-G1 Therapeutics Announces Initiation Of Phase 1B/2 Clinical Trial Of G1T38 In Combination With Tagrisso", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-16T13:02:00.000+03:00", "replies_count": 0, "uuid": "9e6aea82f9f6fb42786a1957c5b7180a910659a3"}, "author": "", "url": "https://www.reuters.com/article/brief-g1-therapeutics-announces-initiati/brief-g1-therapeutics-announces-initiation-of-phase-1b-2-clinical-trial-of-g1t38-in-combination-with-tagrisso-idUSASC09VVP", "ord_in_thread": 0, "title": "BRIEF-G1 Therapeutics Announces Initiation Of Phase 1B/2 Clinical Trial Of G1T38 In Combination With Tagrisso", "locations": [], "entities": {"persons": [{"name": "pha", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "brief-g1 therapeutics", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "astrazeneca", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 16, 2018 / 10:03 AM / Updated 12 minutes ago BRIEF-G1 Therapeutics Announces Initiation Of Phase 1B/2 Clinical Trial Of G1T38 In Combination With Tagrisso Reuters Staff 1 Min Read \nApril 16 (Reuters) - G1 Therapeutics Inc: \n* G1 THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1B/2 CLINICAL TRIAL OF G1T38 IN COMBINATION WITH TAGRISSO FOR EGFR-MUTANT NON-SMALL CELL LUNG CANCER \n* G1 THERAPEUTICS INC - ASTRAZENECA IS PROVIDING TAGRISSO FOR PHASE 1B/2 CLINICAL TRIAL UNDER NON-EXCLUSIVE CLINICAL TRIAL COLLABORATION AGREEMENT \n* G1 THERAPEUTICS - OPEN-LABEL TRIAL IS EXPECTED TO ENROLL APPROXIMATELY 145 PARTICIPANTS IN TWO PARTS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)", "external_links": [], "published": "2018-04-16T13:02:00.000+03:00", "crawled": "2018-04-16T13:24:58.002+03:00", "highlightTitle": ""}